{
    "nctId": "NCT00932165",
    "briefTitle": "Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin",
    "officialTitle": "Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 451,
    "primaryOutcomeMeasure": "Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with postmenopausal breast cancer (including ovariectomy etc.).\n\nExclusion Criteria:\n\n* Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}